Skip to Main Content
TABLE 1.

Summary of Efficacy and Safety of Canagliflozin as Add-On to Metformin, Metformin Plus Sulfonylurea, and Insulin in Patients With Type 2 Diabetes Over 52 Weeks (3,30–33,50,53)

 Canagliflozin as: 
 Add-on to MET Add-on to MET + SU Add-on to insulin 
Changes in key efficacy parameters 
Body weight (kg) GLIM PBO PBO 
  Baseline: 86.6  Baseline: 90.8  Baseline: 97.7 
  Change: +1.0% (+0.7)  Change: –0.9% (–1.0)  Change: +0.1% (+0.1) 
 CANA 100 mg CANA 100 mg CANA 100 mg 
  Baseline: 86.8  Baseline: 93.5  Baseline: 96.9 
  Change: –4.2% (–3.7)  Change: –2.2% (–2.0)  Change: –2.4% (–2.3) 
 CANA 300 mg CANA 300 mg CANA 300 mg 
  Baseline: 86.6  Baseline: 93.5  Baseline: 96.7 
  Change: –4.7% (–4.0)  Change: –3.2% (–3.1)  Change: –3.1% (–3.0) 
 SITA SITA  
  Baseline: 87.6  Baseline: 89.6  
  Change: –1.3% (–1.2)  Change: +0.3% (+0.1)  
 CANA 100 mg CANA 300 mg  
  Baseline: 88.7  Baseline: 87.6  
  Change: –3.8% (–3.3)  Change: –2.5% (–2.3)  
 CANA 300 mg   
  Baseline: 85.4   
  Change: –4.2% (–3.7)   
 Canagliflozin as: 
 Add-on to MET Add-on to MET + SU Add-on to insulin 
Changes in key efficacy parameters 
Body weight (kg) GLIM PBO PBO 
  Baseline: 86.6  Baseline: 90.8  Baseline: 97.7 
  Change: +1.0% (+0.7)  Change: –0.9% (–1.0)  Change: +0.1% (+0.1) 
 CANA 100 mg CANA 100 mg CANA 100 mg 
  Baseline: 86.8  Baseline: 93.5  Baseline: 96.9 
  Change: –4.2% (–3.7)  Change: –2.2% (–2.0)  Change: –2.4% (–2.3) 
 CANA 300 mg CANA 300 mg CANA 300 mg 
  Baseline: 86.6  Baseline: 93.5  Baseline: 96.7 
  Change: –4.7% (–4.0)  Change: –3.2% (–3.1)  Change: –3.1% (–3.0) 
 SITA SITA  
  Baseline: 87.6  Baseline: 89.6  
  Change: –1.3% (–1.2)  Change: +0.3% (+0.1)  
 CANA 100 mg CANA 300 mg  
  Baseline: 88.7  Baseline: 87.6  
  Change: –3.8% (–3.3)  Change: –2.5% (–2.3)  
 CANA 300 mg   
  Baseline: 85.4   
  Change: –4.2% (–3.7)   

CANA, canagliflozin; GLIM, glimepiride; MET, metformin; PBO, placebo; SITA, sitagliptin; SU, sulfonylurea.

Close Modal

or Create an Account

Close Modal
Close Modal